U.S. Cath Labs Market Size, Trends, Share, Growth | Report 2022-2030
The U.S. cath labs market size was estimated at around USD 13.66 billion in 2021 and it is projected to hit around USD 21.96 billion by 2030, growing at a CAGR of 5.4% from 2022 to 2030.
Report Highlights
The high incidence of heart disease in the U.S., the improving spending capacity of the residents, the growing number of therapeutic surgeries, and technological advancements are fueling market growth. In addition, the increasing preference for minimally invasive surgeries is expected to offer growth opportunities for the market.
The volume of heart disease diagnostics and surgeries performed is increasing in the U.S. As per the American Heart Association, more than 1 million catheterization surgeries are performed every year. The northeastern and southeastern regions in the U.S. have the highest hospitalization rates for heart disease patients. Michigan, Ohio, West Virginia, Alabama, Georgia, North Carolina, and Kentucky are the states having the highest hospitalization rates for heart disease as per the CDC. This indicates the high requirement for heart disease treatment and the huge accessibility to service in the U.S.
The COVID-19 pandemic resulted in a decline in the number of cardiac procedures as COVID-19 care was the primary focus wherein several cath labs were converted into intensive care units for COVID-19 patients temporarily. The cath labs also witnessed a shortage of medical devices due to disruption in the supply chain during the initial phase of the pandemic. Automated external defibrillators having application in cardiac diagnostic procedures were the equipment having the least supply during the pandemic. The later phase of the pandemic witnessed increased demand for services owing to the rise in heart disease resulting from inactivity during the pandemic.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 13.66 billion |
| Revenue Forecast by 2030 | USD 21.96 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.4% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Component, facility type |
| Companies Covered |
Koninklijke Philips N.V.; Shimadzu Corporation; GE Healthcare; Johnson & Johnson; B. Braun Melsungen AG; Siemens Healthineers; Medtronic; Cardinal Health, Inc.; Boston Scientific Corporation; Abbott Laboratories |
Component Insights
In 2021, the services segment dominated the market with a revenue share of over 69.05%. This is due to the rising prevalence of cardiovascular diseases in the U.S. The service segment is sub-segmented into therapeutic and diagnostic services. Therapeutic services accounted for a dominant share in 2021 due to the majority of patients having heart diseases in the U.S. requiring long therapy. Based on components, the market is categorized into service and equipment.
Alabama, West Virginia, Louisiana, and Kentucky are the least heart-healthy states in the U.S., thus having a higher need for diagnostic and therapeutic services. Among all cardiovascular disorders, heart attacks are most prevalent, with every 40 seconds one American having a heart attack wherein 1 in 5 attacks is a silent one. In such cases, direct therapeutic services are required. The southeastern and northeastern states have funding from national and state organizations for the management of heart diseases, thus fueling segment growth in the region.
The equipment segment is expected to witness lucrative growth over the forecast period owing to the increasing need for diagnostic and therapeutic surgical procedures. The preference for minimally invasive surgeries is resulting in the launch of new equipment in the market. For instance, in July 2021, Siemens Healthineers launched a new Artis Icono angiography system enabling high accuracy in diagnostics. The rising burden of expenditure on the cardiovascular sector in the U.S. is resulting in a requirement for cost-effective equipment enabling outpatient facilities to adopt advanced equipment to increase the quality of services. The trend of value-based services in the U.S. is resulting in higher adoption of new equipment by the cath labs.
Facility Type Insights
In 2021, hospital-based labs dominated the market with a revenue share of over 94.8%. This can be attributed to the increasing number of corporate hospital-based cath labs, favorable reimbursement, and the accessibility of top-quality care and equipment in hospital-based settings. Based on facility type, the market is categorized into hospital-based labs and independent labs.
The regulations favored hospitals and provide better reimbursement for hospital inpatient settings. In addition, the hospital-based cath labs unit is among the top cath labs in the nation. In New York, The Mount Sinai hospital cath labs have been rated as the best cath lab in the state. The adoption of the latest technology for safe and effective diagnosis and treatment is resulting in a higher preference for such settings. For instance, in Aug 2019, Jackson memorial hospital-based cath lab became the first in the state of Florida to adopt Alphenix Core+, a catheterization imaging technology developed by Cannon Medical System.
Freestanding cath labs are witnessing lucrative growth owing to the lower cost of services and less time-consuming treatment. In addition, during the COVID-19 pandemic, the patients preferred independent labs due to the risk of infection in hospital-based settings and inefficiency in hospital-based services due to the COVID-19 burden. Moreover, the patients prefer independent cath labs due to the non-requirement of admission post-surgery resulting in quick recovery. The ambulatory catheterization centers facilitate better personalized patient care, which is not often possible in a hospital-based setting. However, the removal of various procedures from the Medicare reimbursement list in 2021 is limiting the segment growth.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Cath Labs Market
5.1. COVID-19 Landscape: U.S. Cath Labs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Cath Labs Market, By Component
8.1. U.S. Cath Labs Market, by Component, 2022-2030
8.1.1. Services
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Equipment
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. U.S. Cath Labs Market, By Facility Type
9.1. U.S. Cath Labs Market, by Facility Type, 2022-2030
9.1.1. Independent Labs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hospital-based Labs
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. U.S. Cath Labs Market, Regional Estimates and Trend Forecast
10.1. U.S.
10.1.1. Market Revenue and Forecast, by Component (2017-2030)
10.1.2. Market Revenue and Forecast, by Facility Type (2017-2030)
Chapter 11. Company Profiles
11.1. Koninklijke Philips N.V.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Shimadzu Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GE Healthcare
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Johnson & Johnson
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. B. Braun Melsungen AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Siemens Healthineers
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medtronic
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cardinal Health, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Boston Scientific Corporation
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Abbott Laboratories
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers